Based on the outcomes derived from Kaplan‒Meier and Cox regression analyses, an innovative nomogram and PRSM predicated on Loxl1 were formulated and subsequently subjected to rigorous validation procedures, providing a highly accurate and practical tool for GBM prognosis assessment in clinical practice. Here, LOXL1 is linked to glioblastoma.